Department of Nephrology, Fundeni Clinical Institute, Fundeni street 258, 022328, Bucharest, Romania.
Department of Nephrology, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
Clin Rheumatol. 2021 Aug;40(8):3285-3297. doi: 10.1007/s10067-021-05646-2. Epub 2021 Feb 17.
We sought to investigate the infection profile and associated risk factors in a compiled cohort of patients with autoimmune disorders with severe renal involvement treated with aggressive immunosuppressive (IS) regimens.
A total of 162 patients with aggressive glomerulonephritis [101 with lupus nephritis (LN), 24 with cryoglobulinemic vasculitis (CryoVasc), and 37 with ANCA-associated vasculitis (AAV)] were retrospectively reviewed for any infection occurrence. Infection incidence, type, site, and grade (1-5) were recorded. Multivariate Cox proportional hazard regression analysis was performed to identify independent risk factors for infections.
A total of 179 infection episodes occurred during a follow-up of 468 patient-years. Eighty-two patients (50.6%) had at least one infection. The incidence rates of infections and severe infections were 38.2 and 14.3 events per 100 patient-years. Patients with AAV had more infections than those with CryoVasc and LN (100.6, 47.5, and 26.6 infections per 100-patient-years, respectively; p = 0.002). Most patients developed infections early during the initial induction therapy (62.1% in the first 6 months of follow-up). In multivariate Cox regression analysis, high-dose oral corticosteroids (≥ 0.5 mg/kg/day in the first month of induction therapy) was an independent predictor of any infection (HR 2.66; 95% CI, 1.5-4.73), severe infections (HR 2.45; 95% CI, 1.03-5.82), and pulmonary infections (HR 2.91; 95% CI, 1.05-8.01). Pulmonary involvement increased the risk for pulmonary infections (HR 3.67; 95% CI, 1.32-10.1) and severe infections (HR 2.45; 95% CI, 1.01-5.92).
Infections occur frequently with current IS regimens in aggressive glomerulonephritis. Pulmonary involvement and high-dose corticosteroid regimen were the most significant risk factors for infections. Key Points • Infections occur frequently with current immunosuppressive regimens in autoimmune aggressive glomerulonephritis. • High-dose corticosteroids are the major contributors to the risk for serious infections.
我们旨在研究采用强化免疫抑制(IS)方案治疗的伴有严重肾脏受累的自身免疫性疾病患者的感染情况及相关危险因素。
回顾性分析了 162 例强化肾小球肾炎患者(101 例狼疮肾炎[LN],24 例冷球蛋白血症性血管炎[CryoVasc],37 例抗中性粒细胞胞质抗体相关性血管炎[AAV])的任何感染发生情况。记录感染发生率、类型、部位和严重程度(1-5 级)。采用多变量 Cox 比例风险回归分析确定感染的独立危险因素。
在 468 患者年的随访中,共发生 179 例感染。82 例(50.6%)至少发生过一次感染。感染和严重感染的发生率分别为 38.2 和 14.3 例/100 患者年。与 CryoVasc 和 LN 相比,AAV 患者的感染更多(100.6、47.5 和 26.6 例/100 患者年,分别为 p = 0.002)。大多数患者在初始诱导治疗早期发生感染(62.1%在随访的前 6 个月)。多变量 Cox 回归分析显示,高剂量口服皮质类固醇(诱导治疗的第一个月中≥0.5mg/kg/天)是任何感染(HR 2.66;95%CI,1.5-4.73)、严重感染(HR 2.45;95%CI,1.03-5.82)和肺部感染(HR 2.91;95%CI,1.05-8.01)的独立预测因子。肺部受累增加了肺部感染(HR 3.67;95%CI,1.32-10.1)和严重感染(HR 2.45;95%CI,1.01-5.92)的风险。
目前在强化肾小球肾炎中采用的免疫抑制方案常发生感染。肺部受累和大剂量皮质类固醇方案是感染的最重要危险因素。关键点:
当前的免疫抑制方案在治疗自身免疫性疾病所致强化肾小球肾炎时,常发生感染。
大剂量皮质类固醇是导致严重感染的主要原因。